1461049127-2e32691c-68b5-4ddc-aef9-446c5a5f528b

1. A polypeptide comprising an antigenic portion of a M. tuberculosis antigen, or a variant of said antigen that differs only in conservative substitutions andor modifications, wherein said antigen comprises an amino acid sequence encoded by a DNA sequence selected from the group consisting of the sequences recited in SEQ ID NO: 1, 11, 12, 83, 103-108, 125, 127, 129-137, 139 and 140, the complements of said sequences, and DNA sequences that hybridize to a sequence recited in SEQ ID NO: 1, 11, 12, 83, 103-108, 125, 127, 129-137, 139 and 140 or a complement thereof under moderately stringent conditions.
2. A polypeptide comprising an immunogenic portion of a M. tuberculosis antigen, or a variant of said antigen that differs only in conservative substitutions andor modifications, wherein said antigen comprises an amino acid sequence selected from the group consisting of sequences recited in SEQ ID NO: 16-33, 109, 126, 138, 141, 142 and variants thereof.
3. A DNA molecule comprising a nucleotide sequence encoding a polypeptide according to any one of claims 1 and 2.
4. A recombinant expression vector comprising a DNA molecule according to claim 3.
5. A host cell transformed with an expression vector according to claim 4.
6. The host cell of claim 5 wherein the host cell is selected from the group consisting of E. coli, yeast and mammalian cells.
7. A method for detecting M. tuberculosis infection in a biological sample, comprising:
(a) contacting a biological sample with at least one polypeptide according to any one of claims 1 and 2; and
(b) detecting in the sample the presence of antibodies that bind to the polypeptide, thereby detecting M. tuberculosis infection in the biological sample.
8. A method for detecting M. tuberculosis infection in a biological sample, comprising:
(a) contacting a biological sample with at least one polypeptide encoded by a DNA sequence selected from the group consisting of SEQ ID NO: 2-10, 102, 128, the complements of said sequences, and DNA sequences that hybridize to a sequence recited in SEQ ID NO: 2-10, 102, 128; and
(b) detecting in the sample the presence of antibodies that bind to the polypeptide, thereby detecting M. tuberculosis infection in the biological sample.
9. The method of any one of claims 7 and 8 wherein the polypeptide(s) are bound to a solid support.
10. The method of claim 9 wherein the solid support comprises nitrocellulose, latex or a plastic material.
11. The method of any one of claims 7 and 8 wherein the biological sample is selected from the group consisting of whole blood, serum, plasma, saliva, cerebrospinal fluid and urine.
12. The method of claim 11 wherein the biological sample is whole blood or serum.
13. A method for detecting M. tuberculosis infection in a biological sample, comprising:
(a) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, wherein at least one of the oligonucleotide primers is specific for a DNA molecule according to claim 3; and
(b) detecting in the sample a DNA sequence that amplifies in the presence of the oligonucleotide primers, thereby detecting M. tuberculosis infection.
14. The method of claim 13, wherein at least one of the oligonucleotide primers comprises at least about 10 contiguous nucleotides of a DNA molecule according to claim 3.
15. A method for detecting M. tuberculosis infection in a biological sample, comprising:
(a) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, wherein at least one of the oligonucleotide primers is specific for a DNA sequence selected from the group consisting of SEQ ID NO: 2-10, 102, 128; and
(b) detecting in the sample a DNA sequence that amplifies in the presence of the first and second oligonucleotide primers, thereby detecting M. tuberculosis infection.
16. The method of claim 15, wherein at least one of the oligonucleotide primers comprises at least about 10 contiguous nucleotides of a DNA sequence selected from the group consisting of SEQ ID NO: 2-10, 102, 128.
17. The method of claims 13 or 15 wherein the biological sample is selected from the group consisting of whole blood, sputum, serum, plasma, saliva, cerebrospinal fluid and urine.
18. A method for detecting M. tuberculosis infection in a biological sample, comprising:
(a) contacting the sample with one or more oligonucleotide probes specific for a DNA molecule according to claim 3; and
(b) detecting in the sample a DNA sequence that hybridizes to the oligonucleotide probe, thereby detecting M. tuberculosis infection.
19. The method of claim 18 wherein the probe comprises at least about 15 contiguous nucleotides of a DNA molecule according to claim 3.
20. A method for detecting M. tuberculosis infection in a biological sample, comprising:
(a) contacting the sample with one or more oligonucleotide probes specific for a DNA sequence selected from the group consisting of SEQ ID NO: 2-10, 102, 128; and
(b) detecting in the sample a DNA sequence that hybridizes to the oligonucleotide probe, thereby detecting M. tuberculosis infection.
21. The method of claim 20 wherein the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a DNA sequence selected from the group consisting of SEQ ID NO: 2-10, 102, 128.
22. The method of claims 18 or 20 wherein the biological sample is selected from the group consisting of whole blood, sputum, serum, plasma, saliva, cerebrospinal fluid and urine.
23. A method for detecting M. tuberculosis infection in a biological sample, comprising:
(a) contacting the biological sample with a binding agent which is capable of binding to a polypeptide according to any one of claims 1 and 2; and
(b) detecting in the sample a protein or polypeptide that binds to the binding agent, thereby detecting M. tuberculosis infection in the biological sample.
24. A method for detecting M. tuberculosis infection in a biological sample, comprising:
(a) contacting the biological sample with a binding agent which is capable of binding to a polypeptide encoded by a DNA sequence selected from the group consisting of SEQ ID NO: 2-10, 102, 128, the complements of said sequences, and DNA sequences that hybridize to a sequence recited in SEQ ID NO: 2-10, 102, 128; and
(b) detecting in the sample a protein or polypeptide that binds to the binding agent, thereby detecting M. tuberculosis infection in the biological sample.
25. The method of any one of claims 23 and 24 wherein the binding agent is a monoclonal antibody.
26. The method of any one of claims 23 and 24 wherein the binding agent is a polyclonal antibody.
27. A diagnostic kit comprising:
(a) one or more polypeptides according to any one of claims 1 and 2; and
(b) a detection reagent.
28. A diagnostic kit comprising:
(a) one or more polypeptides encoded by a DNA sequence selected from the group consisting of SEQ ID NO: 2-10, 102, 128, the complements of said sequences, and DNA sequences that hybridize to a sequence recited in SEQ ID NO: 2-10, 102, 128; and
(b) a detection reagent.
29. The kit of any one of claims 27 and 28 wherein the polypeptide(s) are immobilized on a solid support.
30. The kit of any one of claims 27 and 28 wherein the detection reagent comprises a reporter group conjugated to a binding agent.
31. The kit of claim 30 wherein the binding agent is selected from the group consisting of anti-immunoglobulins, Protein G, Protein A and lectins.
32. The kit of claim 30 wherein the reporter group is selected from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.
33. A diagnostic kit comprising at least two oligonucleotide primers, at least one of the oligonucleotide primers being specific for a DNA molecule according to claim 3.
34. A diagnostic kit according to claim 32, wherein at least one of the oligonucleotide primers comprises at least about 10 contiguous nucleotide of a DNA molecule according to claim 3.
35. A diagnostic kit comprising at least two oligonucleotide primers, at least one of the primers being specific for a DNA sequence selected from the group consisting of SEQ ID NO: 2-10, 102, 128.
36. A diagnostic kit according to claim 35, wherein at least one of the oligonucleotide primers comprises at least about 10 contiguous nucleotide of a DNA sequence selected from the group consisting of SEQ ID NO: 2-10, 102, 128.
37. A diagnostic kit comprising at least one oligonucleotide probe, the oligonucleotide probe being specific for a DNA molecule according to claim 2.
38. A kit according to claim 37, wherein the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a DNA molecule according to claim 3.
39. A diagnostic kit comprising at least one oligonucleotide probe, the oligonucleotide probe being specific for a DNA sequence selected from the group consisting of SEQ ID NO: 2-10, 102, 128.
40. A kit according to claim 39, wherein the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a DNA sequence selected from the group consisting of SEQ ID NO: 2-10, 102, 128.
41. A monoclonal antibody that binds to a polypeptide according to any one of claims 1 and 2.
42. A polyclonal antibody that binds to a polypeptide according to any one of claims 1 and 2.
43. A fusion protein comprising at least two polypeptides according to any one of claims 1 and 2.
44. A fusion protein comprising at least one polypeptide according to claim 1 and a known M. tuberculosis antigen.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A luminescent material for an LED, comprising:
a compound including a host lattice and a luminescent ion,
wherein the host lattice comprises copper ions and oxygen, and
wherein the compound has the formula
a(M\u2032O).b(M\u2033O).c(Al2O3).d(M\u2032\u20332O3).e(M\u2033\u2033O2).f(M\u2032\u2033\u2033xOy)
wherein
M\u2032 is Cu, or a combination of Cu and Pb;
M\u2033 is Be, Mg, Ca, Sr, Ba, Zn, Cd, Mn, or any combination of thereof;
M\u2032\u2033 is B, Ga, In, or any combination thereof;
M\u2033\u2033 is Si, Ge, Ti, Zr, Hf, or any combination thereof;
M\u2032\u2033\u2033 is a combination of at least one of Y, Gd, and Lu and at least one of Bi, Sn, Sb, Sc, La, Ce, Pr, Nd, Pm, Sm, Eu, Tb, Dy, Ho, Er, Tm, and Yb;
0<a\u22661;
0\u2266b\u22662;
0<c\u22668;
0\u2266d\u22661;
0\u2266e\u22661;
0<f\u22662;
1\u2266x\u22662; and
1\u2266y\u22665.
2. The luminescent material of claim 1, wherein the host lattice comprises lead ions.
3. The luminescent material of claim 1, wherein the luminescent ion comprises at least one element of Eu or Ce.
4. The luminescent material of claim 1, wherein the compound is suitable for emitting light upon excitation with near ultraviolet (UV) or visible light.